Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Immune system diseases

Community pharmacy could detect unknown cases of coeliac disease

Offering a point-of-care finger prick test to customers buying drugs to treat possible symptoms of coeliac disease showed great success in study of 15 community pharmacies.

Finger prick test

Source: Shutterstock

A total of 551 people across 15 community pharmacies were given a finger prick test over a six-month period, with 52 (9.4%) testing positive for immunoglobulin A antibodies, indicating coeliac disease

A proof of concept study has shown how opportunistic testing in community pharmacies may help identify those with coeliac disease who would not otherwise have been tested.

Community pharmacy customers requesting over-the-counter drugs or presenting prescriptions for medicines for the treatment of possible symptoms of coeliac disease, such as irritable bowel syndrome, diarrhoea and other general gastrointestinal problems and anaemias, were offered a free point-of-care finger prick test to check for total immunoglobulin A (IgA) and IgA tissue transglutaminase antibodies (IgA tTGA) — antibodies produced in coeliac disease.

Of the 551 people tested at 15 community pharmacies over six months, 52 (9.4%) tested positive for the antibodies, indicating that coeliac disease might be the cause of their symptoms. Those who tested positive were advised to make an appointment with their GP.

The researchers also found that 277 (50.3%) of those tested were accessing treatment for irritable bowel syndrome, while 142 (25.8%) were presented with diarrhoea.

Reporting their findings in the International Journal of Clinical Pharmacy[1] (online, 8 August 2016), the researchers point out that while previous research has indicated that 1 in 100 people in the UK has coeliac disease, only 24% of those with the condition are diagnosed.

“This proof of concept study has shown that community pharmacies using a point-of-care test can effectively recognise and refer patients for confirmatory coeliac disease testing with high levels of customer and service provider satisfaction,” they say.

All 43 people who completed a satisfaction survey after being tested said that they would recommend the service to others, believing community pharmacy was a suitable place for testing. Participating community pharmacists also believed that the service enabled them to improve relationships with their customers and that local general practices were receptive to the service.

Comprehensive population screening is not recommended in the UK and targeted screening of individuals with related symptoms or associated conditions is recommended. This is predominantly carried out in general practice and involves serological tests for both IgA and IgA tTGA. Adults with a positive serological test result are then referred for endoscopy with biopsy to confirm or exclude coeliac disease.

James Kingsland, president of National Association of Primary Care, says: “Traditionally, the identification and implementation of targeted screening has solely been the role of primary care physicians. They are, however, only able to identify patients who present to them for treatment and advice.

“It is more usual for patients with general gastrointestinal symptoms to self-treat with therapy which is available from pharmacies and supermarkets, which is why community pharmacists are ideally placed to offer the finger prick testing, along with information and advice for those customers,” he says.

Sarah Sleet, chief executive of Coeliac UK, says she is “thrilled with the results of the study” but worries that plans to cut the community pharmacy budget and ongoing efficiencies within the NHS may impact on the roll out of the service.

However, she says: “The direct costs associated with undiagnosed coeliac disease are increased visits to the GP, use of medicines for symptomatic treatment, increased investigations and referral which all cost the NHS more in the long run, while the patient pays the price of reduced quality of life as misdiagnosis can mean an average wait of 13 years to get diagnosed.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20201653

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Finger prick test

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.